SynBiotic Past Earnings Performance
Past criteria checks 0/6
SynBiotic's earnings have been declining at an average annual rate of -91.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
-91.5%
Earnings growth rate
-43.9%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -9.9% |
Return on equity | -114.1% |
Net Margin | -298.4% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How SynBiotic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 8 | -24 | 5 | 0 |
31 Dec 21 | 9 | -13 | 2 | 0 |
31 Dec 20 | 5 | -1 | 1 | 0 |
31 Dec 19 | 0 | 0 | 0 | 0 |
Quality Earnings: SBX is currently unprofitable.
Growing Profit Margin: SBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SBX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: SBX has a negative Return on Equity (-114.08%), as it is currently unprofitable.